Creating value in Life Sciences
We empower our customers to digitise and automate their processes to diagnose disease early and support highly tailored, patient-focused critical care.
We’re pushing technology to the limit in Life Sciences. We’ve helped customers create vaccines faster by streamlining their bioprocess. We’ve enabled them to test samples and receive results in fractions of a second. The fluid control valves we make for ventilators and anaesthesia machines, and the valves, manifolds and precision syringe pumps we make for analytical and diagnostic instruments, have helped save countless lives. As you’d expect where precision and safety are paramount, our world-class manufacturing facilities work to the most stringent global standards.
We significantly extended our product portfolio further into Life Sciences by welcoming Adaptas Solutions into the IMI team in December 2021. Adaptas is a market-leading provider of components and subsystems for ascertaining the composition of chemical compounds within a sample. Adaptas’s deep relationships with global analytical instrument manufacturers and some of the world’s leading scientists allows us to move into adjacent markets and grow fast. Like us, Adaptas has a business model of delivering value by solving customer problems in partnership with them. With our global reach and strength at innovating, customers view us as an extension of their teams. Jay Ray, Senior Vice President, IMI Adaptas, describes the relationship as “being family”.
What are the megatrends in health care?
Urbanisation, sedentary lifestyles and climate change are the biggest global health threats of the 21st century. They will likely increase health risks such as cardiovascular diseases, heat and pollution-related illness and vector-borne diseases. Through our relationship with the scientific research community, we’re attuned to how these trends will impact on the way we diagnose and treat patients.
Healthcare is already starting to look radically different from the one-size-fits-all approach of the past. DNA sequencing combined with real-time monitoring with algorithms and analytical tools present far-reaching opportunities. Our customers can achieve a significantly greater level of accuracy over key inputs like dosage control so they can treat people as individuals and offer a precisely tailored medical regime.
No more waiting for test results
IMI Precision Engineering Technologies now allow health practitioners to test at the point of patient care without having to send samples off to the lab – this will only grow in the coming decades. Point-of-care tests mean practitioners can access test results when they’re with a patient in the GP’s surgery or at the hospital bedside and give them the treatment they need straight away.
Self-testing – something everyone learned how to do during the COVID-19 pandemic – coupled with the power of smartphones is a game-changer. We are engaging with customers on real-time instrumentation intended to analyse exhaled breath and detect biomarkers at very low levels for conditions such as presymptomatic Alzheimer’s or precursors to a heart attack. Picking up the metabolic indicators of diseases early makes successful outcomes much more likely. It is advances like these that make Life Sciences a powerful, critical and attractive high-growth market. It’s one we’re proud to be a part of, innovating to improve life for everyone.
Getting answers in fractions of a second
One of the largest clinical analyser companies in the world asked for our help with advancing their laboratory productivity. They wanted to accelerate processing and improve their use of lab resources, including reagents.
Key laboratory automation facts:
» We helped them build their system and workflow more intelligently and gave them active control over their process
» They were able to speed up their line and significantly increase the number of sample tests per year
» Outcomes include accurate and rapid diagnostics and reduction of errors in the laboratory process
“Our customers value our innate ability to understand the problems they face. The combination of our collaborative nature, understanding of the science, vertical manufacturing capabilities and innovative culture allows us to bring tremendous worth to our customers.”
Jay Ray
Senior Vice President
IMI Adaptas
“Life Sciences has really attractive growth rates and tangible problems that we can solve for a Better World.”
Beth Ferreira
Divisional Managing Director
IMI Precision Engineering
